highly variable drugs-Cmax [Regulatives / Guidelines]

posted by nuka2020 – United Arab Emirates, 2020-11-19 11:09 (103 d 13:15 ago) – Posting: # 22067
Views: 694

According to the GCC guidelines a wider range of Cmax(i.e 75-133%) can be acceptable for HVDP, where it has been demonstrated that the within- subject variability for Cmax of the reference compound in the study is >30%.
But, i have a study which was performed as per Eu guidelines and accordingly, the acceptance criteria for Cmax can be widened to a maximum of 69.84 – 143.19%. Accordingly, the results of Cmax is: 70.46%-141.90%
Need suggestion whether this studies can be acceptable as per GCC guidelines?? :confused::confused:

Complete thread:

Activity
 Admin contact
21,359 posts in 4,460 threads, 1,492 registered users;
online 5 (0 registered, 5 guests [including 4 identified bots]).
Forum time: Wednesday 00:25 CET (Europe/Vienna)

The art and science of asking questions
is the source of all knowledge.    Thomas Berger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5